Botulinum Toxin for Treatment of Dystonia

Therapeutics of Parkinson's Disease and Other Movement Disorders

Volumn , Issue , 2008, Pages 227-240

  Dressler, Dirk ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Basic principles; Botulinum toxin; Dystonia; Indications; Pharmacology

Indexed keywords

EID: 78651231014     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470713990.ch14     Document Type: Chapter

References (66)

1. Alonso-Navarro, H., Puertas, I., Cabrera-Valdivia, F., de ToledoHeras, M., García-Albea, E. and Jimenez-Jimenez, F.J. (2007) Posterior auricular muscle 'dystonia'. European Journal of Neurology, 14, e14-e15.
2. Aramideh, M., Ongerboer de Visser, B.W., Koelman, J.H., Bour, L.J., Devriese, P.P. and Speelman, J.D. (1994) Clinical and electromyographic features of levator palpebrae superioris muscle dysfunction in involuntary eyelid closure. Movement Disorders, 9, 395-402.
3. Barth, K. and Dressler, D. (1993) Die krankengymnastische Zusammenarbeit mit Schiefhalspatienten nach der Behandlung mit Botulinum Toxin. Krankengymnastik, 45, 134-142.
4. Benecke, R., Jost, W.H., Kanovsky, P., Ruzicka, E., Comes, G. and Grafe, S. (2005) A new botulinum toxin type A free of complex-ing proteins for treatment of cervical dystonia. Neurology, 64, 1949-1951.
5. Berweck, S., Feldkamp, A., Francke, A., Nehles, J., Schwerin, A. and Heinen, F. (2002) Sonography-guided injection of botuli-num toxin A in children with cerebral palsy. Neuropediatrics, 2002, 33, 221-223.
6. Brin, M.F., Dressler, D. and Aoki, R. (2004) Pharmacology of botulinum toxin therapy, in Dystonia: Etiology, Clinical Features, and Treatment (eds J. Jankovic, C. Comella and M.F. Brin), Lippincott Williams & Wilkins, Philadelphia, pp. 93-112.
7. Burke, R.E., Fahn, S., Marsden, C.D., Bressman, S.B., Moskowitz, C. and Friedman, J. (1985) Validity and reliability of a rating scale for the primary torsion dystonias. Neurology, 35, 73-77.
8. Consky, E.S., Basinki, A., Belle, L., Ranawaya, R. and Lang, A.E. (1990) The Toronto Westrn Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology, 40 (Suppl 1), 445.
9. Costa, J., Espírito-Santo, C., Borges, A., Ferreira, J.J., Coelho, M., Moore, P. and Sampaio, C. (2005) Botulinum toxin type A therapy for blepharospasm. Cochrane Database of Systematic Reviews, 1, CD004900.
10. Cui, M., Li, Z., You, S., Khanijou, S. and Aoki, R. (2002) Mechanisms of the antinociceptive effect of subcutaneous Bo-tox: inhibition of peripheral and central nociceptive processing. Archives of Pharmacology, 365, R17.
11. Das, C.P., Dressler, D. and Hallett, M. (2006) Botulinum toxin therapy of writer's cramp. European Journal of Neurology, 13 (SUPPL. 1), 55-59.
12. Dong, M., Yeh, F., Tepp, W.H., Dean, C., Johnson, E.A., Janz, R. and Chapman, E.R. (2006) SV2 is the protein receptor for botulinum neurotoxin A. Science, 312, 592-596.
13. Dong, M., Richards, D.A., Goodnough, M.C., Tepp, W.H., Johnson, E.A. and Chapman, E.R. (2003) Synaptotagmins I and II mediate entry of botulinum neurotoxin B into cells. The Journal of Cell Biology, 162, 1293-1303.
14. Dressler, D. (2000a) Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. European Journal of Neurology, 7, 713-718.
15. Dressler, D. (2000b) Complete secondary botulinum toxin therapy failure in blepharospasm. Journal of Neurology, 247, 809-810.
16. Dressler, D. (2000c) Botulinum Toxin Therapy, Thieme Verlag, Stuttgart, New York.
17. Dressler, D. (2002a) Clinical features of secondary failure of botulinum toxin therapy. European Neurology, 48, 26-29.
18. Dressler, D. (2002b) Dysport produces intrinsically more swallowing problems than Botox: Unexpected results from a conversion factor study in cervical dystonia. Journal of Neurology, Neuro-surgery, and Psychiatry, 73, 604.
19. Dressler, D. (2004) New formulation of BOTOX: Complete antibody-induced therapy failure in hemifacial spasm. Journal of Neurology, 251, 360.
20. Dressler, D. and Adib Saberi, F. (2006) Safety aspects of high dose Xeomin therapy. Journal of Neurology, 253 (Suppl 2), II/141.
21. Dressler, D. and Benecke, R. (2003) Autonomic side effects of botulinum toxin type B treatment of cervical dystonia and hyperhidrosis. European Neurology, 49, 34-38.
22. Dressler, D. and Benecke, R. (2006) Xeomin eine neue therapeutische Botulinum Toxin Typ A-Präparation. Aktuelle Neurologie, 33, 138-141.
23. Dressler, D. and Benecke, R. (2007) Pharmacology of therapeutic botulinum toxin preparations. Disability and Rehabilitation, 29, 1761-1768.
24. Dressler, D. and Bigalke, H. (2004) Antibody-induced failure of botulinum toxin type B therapy in de novo patients. European Neurology, 52, 132-135.
25. Dressler, D. and Dirnberger, G. (2000) Botulinum toxin therapy: Riskfactors fortherapy failure. Movement Disorders, 15 (Suppl 2), 51.
26. Dressler, D. and Eleopra, R. (2006) Clinical use of non-A botuli-num toxins: Botulinum toxin type B. Neurotoxicity Research, 9, 121-125.
27. Dressler, D. and Rothwell, J.C. (2000) Electromyographic quantification of the paralysing effect of botulinum toxin. European Neurology, 43, 13-16.
28. Dressler, D., Benecke, R. and Bigalke, H. (2003) Botulinum toxin type B (NeuroBloc) in patients with botulinum toxin type A antibody-induced therapy failure. Journal of Neurology, 250, 967-969.
29. Dressler, D., Eckert, J., Kukowski, B. and Meyer, B.U. (1993) Somatosensorisch Evozierte Potentiale bei Schreibkrampf: Normalisierung pathologischer Befunde unter Botulinum Toxin Therapie. Zeitschrift fäur Elektroenzephalographie und Elektromyographie, 24, 191.
30. Dressler, D., Muenchau, A., Bhatia, K.P., Quinn, N.P. and Bigalke, H. (2002) Antibody induced botulinum toxin therapy failure: Can it be overcome by increased botulinum toxin doses? European Neurology, 47, 118-121.
31. Erbguth, F., Claus, D., Engelhardt, A. and Dressler, D. (1993) Systemic effect of local botulinum toxin injections unmasks subclinical Lambert-Eaton myasthenic syndrome. Journal of Neurology, Neurosurgery, and Psychiatry, 56, 1235-1236.
32. Filippi, G.M., Errico, P., Santarelli, R., Bagolini, B. and Manni, E. (1993) Botulinum A toxin effects on rat jaw muscle spindles. Acta Oto-Laryngologica, 113, 400-404.
33. Frueh, B.R., Felt, D.P., Wojno, T.H. and Musch, D.C. (1984) Treatment of blepharospasm with botulinum toxin. A preliminary report. Archives of Ophthalmology, 102, 1464-1468.
34. Ishikawa, H., Mitsui, Y., Yoshitomi, T., Mashimo, K., Aoki, S., Mukuno, K. and Shimizu, K. (2000) Presynaptic effects of botulinum toxin type A on the neuronally evoked response of albino and pigmented rabbit iris sphincter and dilator muscles. Japanese Journal of Ophthalmology, 44, 106-109.
35. Jabusch, H.C., Zschucke, D., Schmidt, A., Schuele, S. and Al-tenmiiller, E. (2005) Focal dystonia in musicians: treatment strategies and long-term outcome in 144 patients. Movement Disorders, 20, 1623-1626.
36. Jankovic, J. (1996) Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. Journal of Neu-rology, Neurosurgery, and Psychiatry, 60, 704.
37. Jankovic, J., Vuong, K.D. and Ahsan, J. (2003) Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia. Neurology, 60, 1186-1188.
38. Kaji, R., Kohara, N., Katayama, M., Kubori, T., Mezaki, T., Shibasaki, H. and Kimura, J. (1995a) Muscle afferent block by intramuscular injection of lidocaine for the treatment of writer's cramp. Muscle & Nerve, 18, 234-235.
39. Kaji, R., Rothwell, J.C., Katayama, M., Ikeda, T., Kubori, T., Kohara, N., Mezaki, T., Shibasaki, H. and Kimura, J. (1995b) Tonic vibration reflex and muscle afferent block in writer's cramp. Annals of Neurology, 138, 155-162.
40. Mahrhold, S., Rummel, A., Bigalke, H., Davletov, B. and Binz, T. (2006) The synaptic vesicle protein 2C mediates the uptake of botulinum neurotoxin A into phrenic nerves. FEBSLetters, 580, 2011-2014.
41. Marsden, C.D. (1976) The problem of adult-onset idiopathic torsion dystonia and other isolated dyskinesias in adult life (including blepharospasm, oromandibular dystonia, dystonic writer's cramp, and torticollis, or axial dystonia). Advances in Neurology, 14, 259-276.
42. Marsden, C.D. and Sheehy, M.P. (1982) Spastic dysphonia, Meige disease, and torsion dystonia. Neurology, 32, 1202-1203.
43. McMahon, H., Foran, P. and Dolly, J. (1992) Tetanus toxin and botulinum toxins type A and B inhibit glutamate, gamma-aminobutyric acid, aspartate, and met-enkephalin release from synaptosomes: clues to the locus of action. The Journal of Biological Chemistry, 267, 21338-21343.
44. Moore, A.P. and Naumann, M. (2003) Handbook of Botulinum Toxin Treatment, 2nd edn, Blackwell Science, Malden, MA, USA.
45. Morris, J., Jobling, P. and Gibbins, I. (2001) Differential inhibition by botulinum neurotoxin A of cotransmitters released from autonomic vasodilator neurons. American Journal of Physiology. Heart and Circulatory Physiology, 281, 2124-2132.
46. Naumann, M., Albanese, A., Heinen, F., Molenaers, G. and Relja, M. (2006) Safety and efficacy of botulinum toxin type A following long-term use. European Journal of Neurology, 13 (SUPPL. 4), 35-40.
47. Pellizzari, R., Rossetto, O., Schiavo, G. and Montecucco, C. (1999) Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences, 354, 259-268.
48. Pickett, A., Panjwani, N. and O'Keeffe, R.S. (Nov. 2003) Potency of Type A Botulinum Toxin Preparations in Clinical Use. 40th Annual Meeting of the Interagency Botulism Research Coordinating Committee (IBRCC), Atlanta, USA.
49. Probst, T.E., Heise, H., Heise, P., Benecke, R. and Dressler, D. (2002) Rare immunologic side effects of botulinum toxin therapy: brachial plexus neuropathy and dermatomyositis. Movement Disorders, 17 (Suppl 5), S49.
50. Purkiss, J., Welch, M., Doward, S. and Foster, K. (2000) Capsaicin-stimulated release of substance P from cultured dorsal root ganglion neurons: involvement of two distinct mechanisms. Biochemical Pharmacology, 59, 1403-1406.
51. Roggenkamper, P. and Nüssgens, Z. (1993) Frontalis suspension for essential blepharospasm unresponsive to botulinum toxin therapy. First results. German Journal of Ophthalmology, 2, 426-428.
52. Rosales, R.L., Arimura, K., Takenaga, S. and Osame, M. (1996) Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection. Muscle & Nerve, 19, 488-496.
53. Rummel, A., Karnath, T., Henke, T., Bigalke, H. and Binz, T. (2004) Synaptotagmins I and II act as nerve cell receptors for botulinum neurotoxin G. The Journal of Biological Chemistry, 279, 30865-30870.
54. Scott, A.B., Rosenbaum, A. and Collins, C.C. (1973) Pharmacologic weakening of extraocular muscles. Investigative Ophthalmology and Visual Science, 12, 924-927.
55. Scott, A.B. (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Journal of Pediatric Ophthalmology & Strabismus, 17, 21-25.
56. Setler, P. (2000) The biochemistry of botulinum toxin type B. Neurology, 55 (SUPPL. 5), S22-S28.
57. Sheehy, M.P., Rothwell, J.C. and Marsden, C.D. (1988) Writer's cramp. Advances in Neurology, 50, 457-472.
58. Shone, C.C. and Melling, J. (1992) Inhibition of calciumdependent release of noradrenaline from PC12 cells by botulinum type-A neurotoxin. Long-term effects of the neuro-toxin on intact cells. European Journal of Biochemistry, 207, 1009-1016.
59. Tsui, J.K., Eisen, A., Mak, E., Carruthers, J., Scott, A. and Calne, D.B. (1985) A pilot study on the use of botulinum toxin in spasmodic torticollis. The Canadian Journal of Neurological Sciences, 12, 314-316.
60. Tsui, J.K., Eisen, A., Stoessl, A.J., Calne, S. and Calne, D.B. (1986) Double-blind study of botulinum toxin in spasmodic torticollis. Lancet, 2 (8501), 245-247.
61. Welch, M.J., Purkiss, J.R. and Foster, K.A. (2000) Sensitivity of embryonic rat dorsal root ganglia neurons to Clostridium botulinum neurotoxins. Toxicon, 38, 245-258.
62. Whurr, R., Nye, C. and Lorch, M. (1998) Meta-analysis of botuli-num toxin treatment of spasmodic dysphonia: a review of 22 studies. International Journal of Language and Communication Disorders, 33 (Suppl), 327-329.
63. Wiegand, H., Erdmann, G. and Wellhoner, H.H. (1976) 1251-labelled botulinum A neurotoxin: pharmacokinetics in cats after intramuscular injection. Naunyn-Schmiedeberg's Archives of Pharmacology, 292, 161-165.
64. Zeuner, K.E., Bara-Jimenez, W., Noguchi, P.S., Goldstein, S.R., Dambrosia, J.M. and Hallett, M. (2002) Sensory training for patients with focal hand dystonia. Annals of Neurology, 51, 593-598.
65. Zwirner, P. and Dressler, D. (1995) Dystonie als Ursache phar-yngo-laryngealer Motilitatsstürungen. HNO, 43, 498-501.
66. Zwirner, P., Dressler, D. and Kruse, E. (1997) Spasmodic laryngeal dyspnea: a rare manifestation of laryngeal dystonia. European Archives of Oto-Rhino-Laryngology, 254, 242-245.